Xeligekimab
Xeligekimab is a monoclonal antibody that neutralizes interleukin-17A; it is being developed for plaque psoriasis, axial spondyloarthritis, and lupus nephritis. It was in Phase III trials in 2023 and was approved in 2024 in China for the treatment of adult patients with moderate to severe plaque psoriasis.